TILDELING AV FORSKNINGSMIDLER 2015
|
|
|
- Alexia May
- 8 years ago
- Views:
Transcription
1 TILDELING AV FORSKNINGSMIDLER 2015 Søker Prosjekttittel Institusjon Innvilget Beløp Magnar Bjørås Molykære mekansimer for DNA reparasjon Arne Klungland Characterization of novel and known DNA modifications in cancer initiation and progression Generelle driftsmidler Bjarne Bogen T celler i immunovervåkning og immunterapi av kreft Generelle driftsmidler Jorrit Enserink PRECISION MEDICINE FOR ACUTE MYELOID LEUKEMIA PATIENTS Alexandre Corthay Cancer immunotherapy by targeting tumor-infiltrating macrophages Generelle driftsmidler Ole Audun Werner Haabeth Stig Ove Bøe Immunotherapeutic modulation of the bone marrow microenvironment in multiple myeloma Acute promyelocytic leukemia: molecular pathogenesis and mechanism of cure Kvalifiseringsstipend (3 år) Generelle driftsmidler Ingrun Alseth RNA modifications in cancer; the role of Endonuclease V Generelle driftsmidler Kyrre Emblem TREATMENT - Improved Therapy Response Assessment in Metastatic Brain Tumors Eirik Malinen Image-based targeting of cancer
2 Cecilie Kiserud Alexander Fosså Hodgkin`s lymphoma: Risk and prevalence of long-term adverse effects and challenges for the health care service Euronet-PHL-C2 studien-en europeisk randomisert studie for optimalisert behandling av barn og unge med klassisk Hodgkin lymfom Generelle driftsmidler Odd Terje Brustugun Precision oncology in lung cancer Generelle driftsmidler Odd Terje Brustugun Novel EGFR-targeting therapy in non-small cell lung cancer. Treatment effects and resistance mechanisms. Klinisk korttidsstipend Åslaug Helland Why are some cancers more aggressive? Generelle driftsmidler Torgeir Bruun Wyller Kjersti Bruheim Treatment and survival in Norwegian cancer patients beyond 75 years of age Is the new concept of patient tailored radiotherapy safe in small cervical tumours? Klinisk korttidsstipend Stein Andersson Executive functioning in survivors of pediatric brain tumors Generelle driftsmidler Harald Stenmark Cell division and cancer Generelle driftsmidler Camilla Raiborg ER-Endosome Contact: Implications for Tumour Suppressor Pathways, Cell Migration and Invasion Kaisa Haglund Cytokinesis and carcinogenesis Forskerstipend, 1-4. år Generelle driftsmidler Kay Oliver Schink Macropinocytosis in cancer cells - Culprit or Saviour? Kvalifiseringsstipend (3 år) Sebastian Schultz Final steps of autophagosome closure - mechanistic insights and potential role in cancer Kvalifiseringsstipend (3 år) Kirsten Sandvig Endocytosis and intracellular sorting of protein toxins
3 Alicia Llorente Sascha Pust Antoni Wiedlocha Extracellular Vesicles and Prostate Cancer: In Search of Tumorigenesis Mechanisms and Biomarkers Membrane crosslinkers in carcinogenesis: New possibilities for cancer diagnosis and therapy Next generation targeted radionuclide therapy for FGF receptor expressing cancers Generelle driftsmidler Kvalifiseringsstipend (3 år) Generelle driftsmidler Jørgen Wesche Novel regulators of cancer cell migration Generelle driftsmidler Ellen Margrethe Haugsten Ragnhild Lothe Switching off Met signalling - Identification of novel regulators and their relevance in metastatic prostate cancer Kreft, et resultat av genetiske og epigenetiske endringer. Modeller og mekanismer. Kvalifiseringsstipend (3 år) Generelle driftsmidler Guro Elisabeth Lind Epigenetic biomarkers for early detection and monitoring of cancer Generelle driftsmidler Rolf Skotheim Kvalitativ transkriptvariasjon i kreft Heidi Lyng Molecular biomarkers in radiotherapy of cancer Anette Weyergang AN IMMUNE-MEDIATED GATEWAY FOR ELIMINATION OF CANCER Kvalifiseringsstipend (3 år) Generelle driftsmidler Einar Rofstad Tumor-Radiobiologi Generelle driftsmidler Kristian Berg Fotokjemisk internalisering Generelle driftsmidler Randi Syljuåsen DNA damage checkpoint signaling, hypoxia and radiation Generelle driftsmidler Kristin Taskén Targeting therapy resistance in prostate cancer Generelle driftsmidler
4 Leonardo A Meza Zepeda Genome-wide genetic and epigenetic programs in cancer Generelle driftsmidler Ola Myklebost Mesenchymal Cancer Medicine Generelle driftsmidler Gunhild Mælandsmo Kjetil Boye Therapeutic approaches and molecular understanding of metastatic cancer Circulating tumor DNA as a biomarker in gastrointestinal stromal tumor Generelle driftsmidler Kjersti Flatmark Colorectal cancer metastasis - a question of location Generelle driftsmidler Øystein Fodstad Tumor-og molekylærbiologiske studier av metastaser. Utvikling av nye diagnostiske og terapeutiske metoder Generelle driftsmidler Trevor Clancy Systems immunology to guide personalized cancer medicine Kvalifiseringsstipend (3 år) Erlend Bremertun Smeland Kanutte Huse Biology of B cell lymphoma - identification of new diagnostic markers and targets for therapeutic intervention Deep profiling of tumor-cell heterogeneity and tumor-associated T cells in follicular lymphoma Kvalifiseringsstipend (3 år) Johanna Olweus Genetically engineered T cells targeting cancer stem cells Generelle driftsmidler Arne Kolstad Development of novel immunotherapies in malignant lymphoma - discovery of targets and T cell receptors Forskerstipend, 1-4. år Karl-Johan Malmberg Development of Cell Therapies for Malignant Lymphomas Based on New Insights Into Natural Killer Cell Repertoire Diversity Generelle driftsmidler Mouldy Sioud Sébastien Wälchli Improving Dendritic Cell Cancer Vaccine and Antibody Therapy: From Bench to Bedside DEVELOPMENT OF NOVEL STRATEGIES IN CANCER IMMUNOTHERAPY Generelle driftsmidler
5 June Myklebust Deciphering impact of genetic and proteomic alternations on drug sensitivity in B-cell lymphoma Generelle driftsmidler Harald Holte Novel clinical and translational aspects of malignant B-cell lymphomas Forskerstipend, 1-4. år Anders Tveita Immunotherapeutic targeting of tumor-associated macrophages Generelle driftsmidler Hege Elisabeth Giercksky Russnes Intra tumor heterogeneity; from single cell analysis to diagnostic tools. Therese Sørlie Molecular portraits of breast cancer: Translating genomics to the clinical practice Generelle driftsmidler Bjørn Naume Targeting occult tumor cell dissemination in localized breast cancer Vessela Kristensen The genetic Make-up and metabolic profile of breast cancer patients; relation to clinical course and treatment response Generelle driftsmidler Kathrine Røe Redalen BioPicture - Biologic mapping for treatment individualisation in rectal cancer by functional magnetic resonance Kvalifiseringsstipend (3 år) Anne Ree Efficacy and Tolerability to Targeted Combined-Modality Therapy -- Biological Mechanisms in Colorectal Cancer Anne Eskild Are women getting older at last menstrual period, and what may be causes and consequences of high age at menopause? Hilde Nilsen Functional implications of the RNA- and DNA-processing activity of SMUG1 in telomere maintenance, stem cells, and cancer Generelle driftsmidler Hoa Thi Tuyet Tran Acute myeloid leukemia in the elderly Klinisk korttidsstipend
TILDELING AV FORSKNINGSMIDLER 2015 UNIVERSITETET I BERGEN
TILDELING AV FORSKNINGSMIDLER 2015 UNIVERSITETET I BERGEN Søker Prosjekttittel Institusjon Innvilget Beløp Rein Aasland The role of histone acetylation in enhancer function Universitetet i Bergen Thomas
MetAction actionable targets in cancer metastasis from bed to bench to byte to bedside
MetAction actionable targets in cancer metastasis from bed to bench to byte to bedside Kjersti Flatmark MD PhD Departments of Tumor Biology and Gastroenterological Surgery, Oslo University Hospital PIs:
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of
Future Oncology: Technology, Products, Market and Service Opportunities
Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter
Your Certified Professional Cancer Coach. An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer
Your Certified Professional Cancer Coach An Integrative Answer to Cancer Exclusive Professional Program for Patients with Cancer The CPCC Patient Program Nutrition & Lifestyle Oncology A Cancer Diagnosis
An Introduction To Immunotherapy And The Promise Of Tissue Phenomics
An Introduction To Immunotherapy And The Promise Of Tissue Phenomics INSIDE: n The Potential of Immunotherapy n Towards an Understanding of Immunotherapy n Current Approaches to Immunotherapy n The Immunotherapy
Medical Oncology. Rotation Goals & Objectives for rotating residents. General Objectives THE UNIVERSITY OF BRITISH COLUMBIA
THE UNIVERSITY OF BRITISH COLUMBIA Department of Urologic Sciences Faculty of Medicine Gordon & Leslie Diamond Health Care Centre Level 6, 2775 Laurel Street Vancouver, BC, Canada V5Z 1M9 Tel: (604) 875-4301
TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
Cancer SBL101. James Gomes School of Biological Sciences Indian Institute of Technology Delhi
Cancer SBL101 James Gomes School of Biological Sciences Indian Institute of Technology Delhi All Figures in this Lecture are taken from 1. Molecular biology of the cell / Bruce Alberts et al., 5th ed.
Outline. Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment. Introduction. Current clinical practice
Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment Radiation Biology Outline Introduction: Predictive assays in radiation therapy Examples for specific tumors Immunotherapy Summary
Robert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
Achievements Report CURING CANCER. Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for
Achievements Report August 2015 CURING CANCER Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for cancer? Since cancer is complex and comes in many forms, its
What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
Fulfilling the Promise
Fulfilling the Promise Advancing the Fight Against Cancer: America s Medical Schools and Teaching Hospitals For more than a century, the nation s medical schools and teaching hospitals have worked to understand,
Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014
ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the
1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1
1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY
Level 1. Nutrition & Lifestyle Oncology Certificate
Level 1 Nutrition & Lifestyle Oncology Certificate ONE MODULE 1 A Cancer Diagnosis Learn what cancer is; how/why it develops; diagnostic tests; inflammatory/ hormonal connections; 5 most important steps
American Cancer Society Extramural Grants
Page: 1 Clinical Research Professorship (CRP) CRP-14-114-06 Eng, Charis, MD, PhD Cleveland Clinic Foundation Genomic Medicine Institute PTENopathies and Cancer Phenomics 07/01/2014 06/30/2019 $400,000
Future Directions in Cancer Research What does is mean for medical physicists and AAPM?
Future Directions in Cancer Research What does is mean for medical physicists and AAPM? John D. Hazle, Ph.D., FAAPM, FACR President-elect American Association of Physicists in Medicine Professor and Chairman
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
Cancer Services for Adults and Children
UCSF HEALTH Cancer Services for Adults and Children Our world-class clinical and research programs are engaged in the urgent effort to cure cancers and, where cures currently elude us, transform cancer
THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS
Ushering in a new era of cancer medicine Center is ushering in a new era of cancer medicine. Progress that could not even be imagined a decade ago is now being realized in our laboratories and our clinics.
National Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.
Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under
Tildeling av regionale forskningsmidler for 2012 fra Helse Sør Øst RHF. Søker Prosjekttittel Søknadstype Varighet
Søker Prosjekttittel Søknadstype Varighet Tildelt beløp 2012 Akershus universitetssykehus HF Anne Eskild A successful pregnancy: the role of human chorionic gonadotropin (hcg) Tumor hypoxia in rectal cancer
Immuno-Oncology Therapies to Treat Lung Cancer
Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own
Clinical Cancer Research: Alternative IRB Models and Enhancing Progress
Clinical Cancer Research: Alternative IRB Models and Enhancing Progress Lowell E. Schnipper, M.D. Berenson Professor of Medicine Chief, Hematology-Oncology Beth Israel Deaconess Medical Dynamics of Clinical
Foundations of Oncology Nursing Practice
Foundations of Oncology Nursing Practice Course Syllabus Course Lead:, RN, MN, BScN, CON(C) Associate Faculty:, RN, CON(C) Last updated January 27, 2011 Course Description: This online course will introduce
Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine
Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine January 27, 2009 Dear Professors (representative) of departments, Subject:
A Focus on Multiple Myeloma
A Focus on Multiple Myeloma Guest Expert: Madhav Dhodapkar, MD Professor of Hematology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Dr. Ed and Dr.
Multiple Myeloma (Event Driven)
Brochure More information from http://www.researchandmarkets.com/reports/2234830/ Multiple Myeloma (Event Driven) Description: The 2010 multiple myeloma (myeloma) market garnered impressive sales despite
LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH
LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH FUNDING OPPORTUNITY DESCRIPTION 2016 REQUEST FOR APPLICATION (RFA) Lung Cancer Foundation of America (LCFA) and the International
Theories on Metastasis: Innovative Thinking An Advocacy Perspective
Theories on Metastasis: Innovative Thinking An Advocacy Perspective Project LEAD Workshop NBCC Annual Advocacy Conference 2011 Musa Mayer AdvancedBC.org 1 The Big Question If we want to end death from
Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?
Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in
ALK+ lung cancer and the Blood-Brain Barrier (BBB) A concise guide
ALK+ lung cancer and the Blood-Brain Barrier (BBB) A concise guide Contents Section Page number Section 1: Lung cancer and ALK+ NSCLC 3 Section 2: The Blood-Brain Barrier (BBB): What and why? 4 Section
Cancer: DNA Synthesis, Mitosis, and Meiosis
Chapter 5 Cancer: DNA Synthesis, Mitosis, and Meiosis Copyright 2007 Pearson Copyright Prentice Hall, 2007 Inc. Pearson Prentice Hall, Inc. 1 What Is Cancer? Benign tumors do not invade surrounding tissue
1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT
1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT Learning that your pet has a diagnosis of cancer can be overwhelming. We realize that your pet
What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:
Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
Cancer Research Experience Program. Opportunities for Howard University Students. 2016 Program Year
R O S W E L L PA R K C A N C E R I N S T I T U T E S Cancer Research Experience Program Opportunities for Howard University Students 2016 Program Year THE ROSWELL PARK/HOWARD UNIVERSITY CANCER SCHOLARS
New strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
Avastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
Cancer is the leading cause of death for Canadians aged 35 to 64 and is also the leading cause of critical illness claims in Canada.
Underwriting cancer In this issue of the Decision, we provide an overview of Canadian cancer statistics and the information we use to make an underwriting decision. The next few issues will deal with specific
Immunotherapy Concept Turned Reality
Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a
30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens
Advancesincancer immunologyand immunotherapy 30-31 October2015 Royal Olympic Hotel Athens announcement Organizer Hellenic Oncology Research Group (HORG) Symposium chairs N. Kentepozidis, A. Kotsakis, M.
4/15/2013. bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o. anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma
Chapter Sixteen Oncology bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o Combining Forms Prefixes and Suffixes Carcinogenesis anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma Causes of cancer
Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center
Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Bodnar s Law Simple Things are Important Very Simple Things are Very Important
One out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3
1. What is cancer? 2. What causes cancer?. What causes cancer? 3. Can cancer be prevented? The Facts One out of every two men and one out of every three women will have some type of cancer at some point
The Brain and Spine CenTer
The Br ain and Spine Center Choosing the right treatment partner is important for patients facing tumors involving the brain, spine or skull base. The Brain and Spine Center at The University of Texas
LESSON 3.5 WORKBOOK. How do cancer cells evolve? Workbook Lesson 3.5
LESSON 3.5 WORKBOOK How do cancer cells evolve? In this unit we have learned how normal cells can be transformed so that they stop behaving as part of a tissue community and become unresponsive to regulation.
Targeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
Ph.D. in Molecular Medicine
Ph.D. in Molecular Medicine and Translational Research College of Medicine 1. Introduction: The College of Medicine, while consolidating on its undergraduate innovative educational programs, decided to
The Biological Basis of Cancer. Annie Young, Professor of Nursing, University of Warwick, University Hospitals Coventry and Warwickshire
The Biological Basis of Cancer Annie Young, Professor of Nursing, University of Warwick, University Hospitals Coventry and Warwickshire Aim of Presentation By the end of this presentation you will: Be
World Class Personalized Cancer Medicine
World Class Personalized Cancer Medicine The Princess Margaret Cancer Centre Strategy 2013 2018 2015 Edition Contents 4 The Princess Margaret Cancer Centre 6 Accountability 7 Our Core Activities and Resources
This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking
Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties
CHAPTER 2: UNDERSTANDING CANCER
CHAPTER 2: UNDERSTANDING CANCER INTRODUCTION We are witnessing an era of great discovery in the field of cancer research. New insights into the causes and development of cancer are emerging. These discoveries
Groundbreaking Collaborative Clinical Trial Launched
Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)
ACUTE MYELOID LEUKEMIA (AML),
1 ACUTE MYELOID LEUKEMIA (AML), ALSO KNOWN AS ACUTE MYELOGENOUS LEUKEMIA WHAT IS CANCER? The body is made up of hundreds of millions of living cells. Normal body cells grow, divide, and die in an orderly
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
National Cancer Institute Research on Childhood Cancers. In the United States in 2005, approximately 9,510 children under age 15 will be
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s National Cancer Institute
A leader in the development and application of information technology to prevent and treat disease.
A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today
MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
68 th Meeting of the National Cancer Institute (NCI) NCI Council of Research Advocates (NCRA) National Institutes of Health (NIH)
68 th Meeting of the National Cancer Institute (NCI) NCI Council of Research Advocates (NCRA) National Institutes of Health (NIH) Updates on NCI Programs Building 31, C Wing, Conference Room 6 NIH Campus
If you were diagnosed with cancer today, what would your chances of survival be?
Q.1 If you were diagnosed with cancer today, what would your chances of survival be? Ongoing medical research from the last two decades has seen the cancer survival rate increase by more than 40%. However
The Past, Present & Future of Cancer Immunotherapy:
Article The Past, Present & Future of Cancer Immunotherapy: An Overview Recently BioWorld called cancer immunotherapy white hot based on unprecedented investments in private companies, partnerships between
Us TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
Update in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
Developments in Biomarker Identification and Validation for Lung Cancer
Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options
Pathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France
Pathophysiology of bone metastasis : how does it apply to pain treatment in palliative care? JP Vuillez, Grenoble, France Bone metastases 70 % of prostate and breast cancers 30 % of lung, bladder and thyroid
Early detection of breast cancer
Early detection of breast cancer Professor Denise Kendrick Division of Primary Care 1 5/26/2016 Average Number of New Cases Per Year and Age-Specific Incidence Rates per 100,000 Population Females, UK
Report series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
Cancers: Solid Tumor. About Solid Tumours Cancer Basics. Writer: Maya Chaddah Editor: Lisa Willemse Reviewer: Sheila Singh
Cancers: Solid Tumor About Solid Tumours Cancer Basics Causes, risk factors and staging Treatment How are Stem Cells Helping in the battle against solid tumours? History of hematopoietic stem cell transplantation
Centre for. Biomedicine Annual report 2012
Centre for Cancer Biomedicine Annual report 2012 content 2 3 4 Comments by the directors 6 PRESENTATION OF EMPLOYEES 8 highlights 26 Research Groups 38 associated Groups 43 Clinical associates 44 5-year
How To Raise Money For Rare Cancer Research
Our 2014 Impact Funding Allocations Cycle for Survival funds promise: Our donations launch and accelerate research studies and clinical trials that drive discovery. By helping fill the funding gap in rare
Understanding Metastatic Disease
Supported by an unrestricted educational grant from Pfizer Understanding Metastatic Disease Metastatic disease or metastases are phrases that mean the same as Secondary cancer. This means that the cancer
Master Online Study Program @dvanced Oncology. Study part time team up internationally!
Master Online Study Program @dvanced Oncology Study part time team up internationally! Ulm University is developing an innovative international postgraduate study program @dvanced Oncology addressing clinical
SUMMARY. Randolph Fillmore, Florida Science Communications
SUMMARY Randolph Fillmore, Florida Science Communications The H. Lee Moffitt Cancer Center held its first Advanced Prostate Cancer Collaboration roundtable discussion November 24, 2008. The roundtable
Resumen Curricular de los Profesores. Jesse Boehm
Resumen Curricular de los Profesores Jesse Boehm Jesse Boehm is the assistant director of the Cancer Program at the Broad Institute. In this role, he works closely with Cancer Program director Todd Golub
Osteosarcoma: treatment beyond surgery
Osteosarcoma: treatment beyond surgery Eric Chow, DVM DACVS Sue Downing, DVM DACVIM-Oncology Providing the best quality care and service for the patient, the client, and the referring veterinarian. Osteosarcoma
Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.
Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)
at a critical moment Physician Suggestion Line...
Radiation Oncology Exceptional care at a critical moment When your patients require radiation therapy, they deserve the very best care available to them. The Department of Radiation Oncology provides exceptional
Griffith University - Case for Support. Mesothelioma Research Program
Griffith University - Case for Support Mesothelioma Research Program Professor Lyn Griffiths Director, Dean, Research and Director, Genomics Research Centre (GHI) Established in 2007. Integrated health
MATWIN Programme 2015 Support for the Proof of Concept Project Application Form
MATWIN Programme 2015 Support for the Proof of Concept Project Application Form For internal use only: Cancéropôle partner: Date of receipt: File number: MATWIN is a nationwide programme that identifies
Are children more sensitive to radiation than adults?
Are children more sensitive to radiation than adults? By Madan M. Rehani Director of Radiation Protection, European Society of Radiology There is a commonly held belief that children may be two to three
Lung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
The following information is only meant for people who have been diagnosed with advanced non-small cell
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
Leukemias and Lymphomas: A primer
Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes
USD 1,500,000 for cancer researchers in Switzerland and Spain
Press release SAKK/RTFCCR/Gateway Research Grant: Winning studies announced USD 1,500,000 for cancer researchers in Switzerland and Spain Five researchers were awarded with the SAKK/RTFCCR/Gateway Research
CancerStemCell Markers in Lung Cancers: Proofsof. Reservations. Lourdes Cortes-Dericks, PhD University of Hamburg Hamburg, Germany
CancerStemCell Markers in Lung Cancers: Proofsof ConceptsandSome Reservations Lourdes Cortes-Dericks, PhD University of Hamburg Hamburg, Germany Lung cancer: highest death rate and poorest patient survival
A comprehensive treatment and research center for people with brain tumors
Brain Tumor Center A comprehensive treatment and research center for people with brain tumors UC Brain Tumor Center Our Collaborative Team The medical and surgical management of brain tumors requires a
Treating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
White Paper. Understanding the Scope and Challenges of Childhood Cancer. Introduction
White Paper Understanding the Scope and Challenges of Childhood Cancer Introduction Imagine a world without childhood cancer. No painful chemotherapy treatments. No emotional stress on children and their
EACR AACR SIC. from Cancer Biology to the Clinic. Advance Programme & Call for Abstracts ITALY 20-23 JUNE. Anticancer Drug Action and Drug Resistance:
Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic Organised by: Advance Programme & Call for Abstracts -- ORGANIZING COMMITTEE n Richard Marais (UK) - Conference Co-Chair n
Department of BioScience Technology Chung Yuan Christian University 2015/08/13
Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Cancer Cells Cancer, the 1st leading cause of death, is an example of a disease that arises from abnormalities in cell function
How To Learn More About Melanoma
PROGRAMMA SCIENTIFICO MELANOMA BRIDGE 2012, DECEMBER 2 ND -4 TH 2012 Presidents: Paolo A. Ascierto, Francesco M. Marincola and Nicola Mozzillo Scientific Board Paolo A. Ascierto Gennaro Ciliberto Bernard
2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant
2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant Guidelines & General Instructions for Application KEY DATES: Application Release Date: December 12, 2012 Application Deadline: February